Immudex

Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. The foundation of Immudex is not a product. Since 2013, Immudex has been working with the US Cancer Immuno­therapy Consortium and the European Association for Cancer Immunotherapy to assess immune monitoring proficiency and thus, align laboratories worldwide to deliver robust insights and build an authoritative research landscape on immunity. Immudex is the proud global distributor of the high-quality easYmer® MHC monomers manufactured by immunAware. Instead, it is the certainty that a detailed understanding of the immune system can expand medicine boundaries and open new therapeutic and diagnostic opportunities. At the core of our vision is the desire to be there for researchers and clinicians worldwide, helping them develop more effective immune-based therapeutics and diagnostics. Thus, we strive to position ourselves in the midst of scientific efforts and operate as facilitators.